Subscribe To
NTLA / Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely
NTLA News
By The Motley Fool
October 28, 2023
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
Intellia will soon start a phase 3 gene-editing trial, the first of its kind. Succeeding with the trial will not be the last hurdle it needs to overco more_horizontal
By Zacks Investment Research
October 23, 2023
Intellia (NTLA) Focuses on Developing Gene-Editing Therapies
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage developme more_horizontal
By Zacks Investment Research
October 19, 2023
Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopath more_horizontal
By Zacks Investment Research
October 16, 2023
Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA more_horizontal
By The Motley Fool
October 10, 2023
Down 45%, Is Intellia a Buy?
Intellia has declined over the past year even as its candidates for severe diseases have advanced in clinical studies. The company aims to launch a ph more_horizontal
By The Motley Fool
October 10, 2023
This Cathie Wood Stock Is Poised to Double, Says Wall Street
Intellia's leading candidates look promising, but there's a long way to go before they hit the market. If the company can deliver regular clinical and more_horizontal
By The Motley Fool
October 3, 2023
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
Intellia Therapeutics has a pair of promising gene-editing therapies in the works. It also has a highly technically advanced program that could enter more_horizontal
By Reuters
October 3, 2023
Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their research collaboration to develop additional CRISPR-based gene editing therapi more_horizontal